Kiromic | ApexOnco - Clinical Trials news and analysis

x

“It's very intuitive and always up-to-date”

Monika Vogelmann

Head of Market Insights Oncology Europe

Daiichi Sankyo

Click here for more information

Data insights

6 October 2023

Three mystery phase 1 entrants

Bristol, AbbVie and Jiangsu HengRui move to enter clinical trials with undisclosed mechanisms of action.

Subscribe to Kiromic